TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier
As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain ba...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2019-05-01
|
| Rangatū: | Marine Drugs |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1660-3397/17/5/286 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|